Annuity Payments For Costly One-Off Drugs Are No Magic Bullet
Paying for expensive one-off treatments in installments rather than one lump sum could be appropriate for some products, but fails to address wider systemic problems.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.